Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00003496

Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer

Small Cell Lung Cancer Extensive Stage Clinical Trial

Official title:
Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Small Cell Carcinoma of the Lung

Clinical Trial Summary

Current therapies for Recurrent or Extensive-Stage Small Cell Lung Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Recurrent or Extensive-Stage Small Cell Lung Cancer.

PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Recurrent or Extensive-Stage Small Cell Lung Cancer.

Clinical Trial Description

OVERVIEW: This is a single arm, open-label study in which patients with Recurrent or Extensive-Stage Small Cell Lung Cancer receive gradually escalating doses of intravenous Antineoplaston therapy (Atengenal + Astugenal) until the maximum tolerated dose is reached. Treatment continues up to12 months in the absence of disease progression or unacceptable toxicity.

OBJECTIVES:

- To determine the efficacy of Antineoplaston therapy in patients with Recurrent or Extensive-Stage Small Cell Lung Cancer, as measured by an objective response to therapy (complete response, partial response or stable disease).

- To determine the safety and tolerance of Antineoplaston therapy in patients with Recurrent or Extensive-Stage Small Cell Lung Cancer.

- To determine objective response, tumor size is measured utilizing MRI scans, which are performed every 8 weeks for the first two years, every 3 months for the third and fourth years, every 6 months for the 5th and sixth years, and annually thereafter. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00003496
Study type Interventional
Source Burzynski Research Institute
Contact
Status Terminated
Phase Phase 2
Start date March 7, 1996
Completion date February 5, 2004
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02179528 - Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC) Phase 2
Recruiting NCT06030258 - IN10018 Combination Therapy in Treatment-naïve ES-SCLC Phase 1/Phase 2
Recruiting NCT05384015 - Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer Phase 2
Not yet recruiting NCT05745350 - First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC Phase 2
Completed NCT03325816 - Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer Phase 1/Phase 2
Recruiting NCT05856695 - A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC) Phase 2
Completed NCT03059667 - Immunotherapy as Second-line in Patient With Small Cell Lung Cancer Phase 2
Active, not recruiting NCT03923270 - Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer Phase 1
Not yet recruiting NCT06348797 - Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC Phase 1
Active, not recruiting NCT04462276 - Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease Phase 2
Recruiting NCT05680922 - DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer Phase 1
Not yet recruiting NCT04967625 - A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC Phase 2
Recruiting NCT04659785 - A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC） Phase 1/Phase 2
Active, not recruiting NCT04670445 - Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer N/A
Not yet recruiting NCT05066945 - Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients
Recruiting NCT05945745 - Molecular Analysis and Treatment Options of SCLC
Not yet recruiting NCT03755115 - SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer Phase 2
Terminated NCT05027867 - KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer Phase 2
Recruiting NCT06187740 - Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy Phase 1
Recruiting NCT03994744 - Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC Phase 2